Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...

NEXT-GENERATION sequencing use rose in advanced cancer, but access remained uneven across socioeconomic, racial, and insurance groups. Next-Generation Sequencing Trends Across Tum ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...

Mount Sinai Health System, based in New York City, will adopt an artificial intelligence-powered platform from SOPHiA GENETICS to expand its cancer research and genomic testing capabilities. The ...

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...

Breast cancer is one of the most common malignancies worldwide, and mutations in the PI3K/AKT/mTOR (PAM) signaling pathway ...

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

BURBANK, Calif. (KABC) -- Cancer is not a welcome diagnosis, but breakthroughs in genetic sequencing and immunotherapy are making some cancers easier to treat than others. A local father and ...

Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...